Activity Title: The Role Of PD-1 Inhibitors in The Evolving Landscape of Advanced Cutaneous Squamous Cell Carcinoma Treatment

Release Date: April 15, 2019

Expiration Date: April 15, 2020

1.0 hour activity | ACCME, ANCC, ACPE

Activity Overview:
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer after basal cell carcinoma (BCC). The incidence of cSCC in the United States and throughout the world is increasing. In the US, each year 200,000-400,000 new cases of cSCC are expected, with disease-related death occurring in more than 3,000 people with cSCC. Most patients with cSCC are cured with surgery, however, in some patients these tumors can become metastatic or locally advanced and are not cured by surgery or radiation therapy. A large follow-up study of the US population showed that the incidence of invasive cSCC, which may advance or metastasize, increased during an 18-year follow up period. Advanced cSCC is a life-threatening condition, and currently no systemic therapies are approved. Recently, immune checkpoint inhibitors that block the PD-1/PD-L1 pathway have shown promise in the treatment of advanced cSCC. Dermatologists play an important role in the management of cSCC, and their awareness about recent developments in risk stratification, targeted therapies, and follow-up for patients with advanced cSCC is crucial to improve prognosis.

Target Audience:
This activity is designed to meet the needs of dermatologists, oncologists physician assistants, pharmacists, nurses/nurse practitioners and other health care practitioners who treat SCC.

Learning Objectives:
Upon completion of the educational activity, participants should be able to:

• Outline strategies for the identification of high-risk patients with cSCC based on the latest staging systems, risk factors and guidelines
• Review the mechanisms of action and rationale for the use of PD-1 inhibitors in advanced cSCC
• Interpret the latest clinical trial data about the efficacy and safety of PD-1 inhibitors in advanced cSCC
• List the potential dermatologic adverse events resulting from immune checkpoint inhibitor therapy in advanced cSCC, as well as their appropriate management in order to optimize patient outcomes

Criteria for Success
In order to receive credit, participants should watch the entire video. Once you have watched the video, you will continue to the online quiz and evaluation. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba South Beach Symposium. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 1.0 Contact Hours.

Pharmacists
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 1.0 contact hour(s) (0.1 CEUs). UAN 0077-9999-19-014-H04-P. Initial release: April 15, 2019

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba South Beach Symposium

Commercial Support:
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

Required hardware/software:
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.